• NIA Innovations & COVID-19
  • Newsletter Sign-Up
  • FAQs
  • Case Studies
  • Contact Us
NIANIANIANIA
  • About
    • What the NIA offers
    • Selection Process
    • Core Team
    • Mentors
    • Partners
    • Collaborate
    • Apply
  • Fellows and Innovations
    • Overview
    • Fellows
    • Innovations
    • Alumni
  • Latest
    • Events
    • News & blogs

Newly published study shows population genetic testing saves money and lives

    Home News Newly published study shows population genetic testing saves money and lives
    NextPrevious

    Newly published study shows population genetic testing saves money and lives

    By Morgan McKean | News | Comments are Closed | 17 July, 2020 | 0

    NIA Fellow Ranjit Manchanda (2019) recently published an international study on broadening cancer BRCA gene testing to entire populations, which showed it is cost effective and could prevent millions more cancer cases worldwide. 

    Read an overview of the paper below and find the full text, published in Cancers, here.

    Screening entire populations for breast and ovarian cancer gene mutations could prevent millions more breast and ovarian cancer cases across the world compared to current clinical practice, according to an international study led by Queen Mary University of London. The research also shows that it is cost effective in high and upper-middle income countries.

    The most well-known breast and ovarian cancer causing genes are BRCA1 and BRCA2. These gene mutations cause around 10-20 per cent of ovarian and 6 per cent of breast cancers. If mutation carriers could be identified before they develop disease, most of these cancers could be prevented by drugs, increased screening or surgery.

    Prof Ranjit Manchanda

    Current clinical guidelines globally only recommend genetic testing for high-risk women, for example, if they fulfil certain clinical criteria or if there is a strong family history of breast or ovarian cancer. However, over 50 per cent of BRCA carriers do not meet these criteria so are not tested, and over 97 per cent of BRCA carriers in the UK population remain unidentified.

    This new study was supported by the NHS Innovation Accelerator Fellowship and women’s cancer charity The Eve Appeal and published in the journal Cancers. The researchers estimated the cost-effectiveness and health impact of BRCA testing in the general population, compared with current standard clinical testing of women designated as high risk, in countries considered high income (UK/USA/Netherlands), upper-middle income (China/Brazil), and low-middle income (India).

    The researchers modelled a number of scenarios of population based BRCA-testing and compared the costs and health impact to the current family history based policy. Cost effectiveness was calculated from both a societal and a payer perspective.  A payer perspective only includes medical costs incurred by the health system or health providers (such as costs of genetic testing, screening, prevention and cancer treatment). A societal perspective also takes into account costs such as the impact of income lost from inability to work and shorter life spans due to cancer.

    The research team found that population based testing was extremely cost effective in high and upper middle income countries from a payer perspective. From a societal perspective it was cost saving in high income countries and cost effective in middle income countries like China and Brazil. Costs of BRCA testing would need to fall to around USD $172 to become cost effective in low income countries like India.

    Findings suggest that population based BRCA testing can prevent an additional 2,319-2,666 breast cancer and 327-449 ovarian cancer cases per million women than the current clinical strategy. In the UK, this translates to preventing an additional 57,700 breast cancer cases (and 5,900 breast cancer deaths) and 9,700 ovarian cancer cases (and 5,900 ovarian cancer deaths), and similar positive results were seen in other countries:

    Breast cancer Ovarian cancer
    Cases prevented Deaths prevented Cases prevented Deaths prevented
    UK 57,708 5,941 9,727 5,919
    USA 269,089 17,446 43,817 24,343
    Netherlands 15,181 1,424 2,557 1,509
    China 1,050,314 121,353 154,756 87,103
    Brazil 156,299 30,509 25,170 15,724
    India 692,571 177,697 97,659 77,948

    Table: Number of cancer cases and deaths that would be prevented over a lifetime if genetic testing was offered to the entire population

    Lead researcher Professor Ranjit Manchanda from Queen Mary University of London said: “General population BRCA testing can bring about a new paradigm for improving global cancer prevention. Why do we need to wait for people to develop a preventable cancer to identify others in whom we can prevent cancer? Strategies and pathways for population testing must be developed to enable population genomics to achieve its potential for maximising early detection and cancer prevention.

    “With the costs of testing falling this can provide huge new opportunities for cancer prevention and changes in the way we deliver cancer genetic testing. This approach can ensure that more women can take preventative action to reduce their cancer risk or undertake regular screening.”

    Dr Rosa Legood, Associate Professor at the London School of Hygiene & Tropical Medicine added: “Our analysis shows that testing all women for BRCA mutations is a more cost-effective strategy which can prevent these cancers in high risk women and save lives. This approach has important implications given the effective options that are available for breast and ovarian cancer risk management and prevention for women at increased risk.”

    Athena Lamnisos, CEO, Eve Appeal said: “We must invest in cancer prevention – this is what will save most lives and also be cost effective within cash-strapped healthcare systems. The evidence emerging from this study is an exciting step forward: we can stop cancer before it has a chance to start through broadening a simple genetic test to a wider population. At The Eve Appeal we work with women given a heart-breaking diagnosis of cancer, this is really hard news to process when they find out they carry a mutation which could have been identified at an early stage and their cancer prevented. For those women and their loved ones, this research provides hope.”

    This research was led by Prof Ranjit Manchanda (Queen Mary University of London) and supported by Dr Rosa Legood (London School of Hygiene & Tropical Medicine). This research was an international collaboration involving research teams from Queen Mary University of London, London School of Hygiene & Tropical Medicine, and involved Amsterdam UMC, Vrije Universiteit Amsterdam (Netherlands); Universidade de Sao Paulo, Sao Paulo (Brazil); Peking University, Beijing (China); Indian Institute of Technology, Kharagpur (India); Presidency University, Kolkata (India); Tata Medical Centre, Kolkata (India); University of Melbourne, Victoria (Australia); Newcastle University (UK).

    No tags.

    Related Posts

    • The new palliative care gold standard

      By admin | Comments are Closed

      By: Julia Riley The EIU’s recent Quality of Death report praised palliative care in the UK as the best in the world, citing the quality and availability of services provided by the NHS and hospice movement as “second toRead more

    • Nervecentre Software win prestigious Building Better Healthcare Award

      By admin | Comments are Closed

      Nervecentre Software in partnership with Nottingham University Hospitals NHS Trust have won the prestigious award for ‘Best Communications and IT product’ at the Building Better Healthcare Awards, held on 4th November 2015, The award isRead more

    • Southend University Hospital NHS Foundation Trust live with Nervecentre electronic observations

      By admin | Comments are Closed

      Southend University Hospital NHS Foundation Trust has now deployed Nervecentre Electronic Observations software using mobiles devices across the hospitals to improve patient safety and communications. Funded through the Nursing Technology Fund, Electronic Observations are now liveRead more

    • Nervecentre in Australia… Success at the ISRRS Symposium in Melbourne


      By admin | Comments are Closed

      Written by Jim Trueman Attendees of the symposium held by the International Society for Rapid Response Systems and Medical Emergency Teams are all clinicians that intuitively recognise the problems that Nervecentre was designed to solve. Read more

    • i-THRIVE: Manchester and Salford’s Integrated Access and Care Pathways 


      By admin | Comments are Closed

      What was the problem you were trying to solve? Central Manchester University Hospitals NHS Foundation Trust (CMFT) provide child and adolescent mental health services (CAMHS) for Manchester and Salford. The move towards Integrated Access andRead more

    • Coordinate My Care Integrates Care Plans into Emis Web

      By admin | Comments are Closed

      Urgent care plans for thousands of London’s most vulnerable patients care are now just a click away for almost 1,000 of their GPs. Plan sharing scheme Coordinate my Care will now be available to 962Read more

    • OWise breast cancer app proven to be effective tool in cancer treatment process

      By admin | Comments are Closed

      Innovative patient support app shown in peer-reviewed medical journal to improve patient-doctor interactions and is recommended by 90% of patients and clinicians OWise breast cancer, the first mobile app to offer patients personalised medical supportRead more

    • OBH featured in TeleMedicine Magazine

      By admin | Comments are Closed

      Telemedicine Magazine included an article on Outcome Based Healthcare (OBH) in their series focusing on the growing trend of doctors getting involved with healthcare start-ups. Rupert, OBH CEO, explained that during his time as aRead more

    NextPrevious
    Contact Us
    nia@uclpartners.com
    @NHSAccelerator
    Newsletter Sign-Up
    Terms and Conditions | Privacy and Cookies
    NHS Innovation Accerlator
    Copyright 2017 NHS Innovation Accelerator
    • Menu
      • Latest
      • Case Studies
      • News and Events
      • Press and Media
      • FAQs (OLD)
      • Contact Us
    • Apply
    • Fellows and Innovations
      • Fellows
      • Innovations
    • Collaborate
    • Accelerator
      • Partners
      • What the NIA offers
      • Selection Process
      • Mentors
    NIA